Grilinctus-L Oral Suspension contains Levocloperastine at a concentration of 20 mg per 5 ml and is indicated for the symptomatic relief of cough associated with upper respiratory tract infections and other non-productive cough conditions. Levocloperastine is a peripherally acting antitussive agent that suppresses the cough reflex by inhibiting sensory nerve endings in the respiratory tract without causing central nervous system depression or sedation. This makes it suitable for use in both adults and children, providing effective cough suppression while minimizing adverse effects commonly associated with centrally acting antitussives. Grilinctus-L is administered orally, with dosage adjusted according to age and severity of symptoms, ensuring optimal therapeutic outcomes. The suspension formulation facilitates ease of administration, particularly in pediatric patients who may have difficulty swallowing tablets or capsules. Common side effects are generally mild and may include gastrointestinal discomfort or allergic reactions, though these are infrequent. Use of Grilinctus-L Oral Suspension should be guided by a healthcare professional, and it is contraindicated in patients with known hypersensitivity to Levocloperastine or any of the excipients. Caution is advised in patients with pre-existing respiratory conditions, and the medication should not be used for productive coughs where expectoration is necessary.